TGA Sponsor – C | M

Cosmetics GMP for Export Purposes (ISO 22716) – Responsible Person

January 12, 2026 adminTGA Sponsor

C | M | S can now act as your European responsible Person. If you are a cosmetics exporter, you may have had been notified by mandated bodies that you require to comply with EC Regulation 1223/2009. What are the requirements for this regulation? All cosmetic products exported to Europe/Asia/NZ will have to be produced according to Good Manufacturing Practices. Cosmetics Good Manufacturing Practices (GMP) is one of the pillars of the New European Regulation for Cosmetics. This regulation sets the requirements to ensure consumers’ safety. Amongst these new legal requirements, all cosmetic products circulating onto the European Market will have to be produced according to Good Manufacturing Practices; a Product Information[…]

Medical Device Single Audit Program (MDSAP) – TGA, CE Marking and more……………………

January 12, 2026 adminTGA Sponsor

Achieve access to multiple markets with a single audit The International Medical Device Regulators Forum (IMDRF) established a working group to develop a standard set of requirements for auditing organizations (Certification Bodies) performing regulatory audits of Medical Device manufacturers’ quality management systems. Termed the Medical Device Single Audit Program (MDSAP), the requirements will be applicable to regulatory authorities, as well as third-party organizations that conduct such audits. What is the MDSAP? The objective of the MDSAP is to develop, manage, and oversee a single audit program that will allow a single regulatory audit of a Medical Device manufacturer, conducted by an MDSAP recognized auditing organization, to satisfy the needs of[…]

MDR 2017/745 and IVDR 2017/746 EU Authorised Representative & EU Importer Services

January 12, 2026 adminTGA Sponsor

Compliance Management Solutions Europe Medical device manufacturers seeking access to the European Union market must comply with the regulatory obligations of MDR (EU) 2017/745, including the appointment of a compliant EU Authorised Representative and, where applicable, an EU Importer. Compliance Management Solutions Europe provides integrated EU Rep and EU Importer services designed to support lawful market access, regulatory continuity, and post-market compliance. As an EU Authorised Representative, Compliance Management Solutions Europe fulfils the responsibilities outlined in Article 11 of the MDR, acting as the manufacturer’s official regulatory presence within the EU. We support manufacturers by verifying the availability and completeness of technical documentation and Declarations of Conformity, maintaining regulatory records,[…]

Transfer Your EU MDR and IVDR Authorized Representative & Importer to CMS – Simplify EU Compliance

January 12, 2026 adminTGA Sponsor

If you manufacture products outside the European Union and sell into the EU market, having a reliable EU Authorized Representative and EU Importer is not optional—it is a regulatory requirement. CMS helps non-EU manufacturers seamlessly transfer their EU Authorized Representative and Importer while ensuring full compliance with EU MDR, IVDR, CE Marking, and EU product regulations. Why Transfer Your EU Rep and Importer to CMS? ✔ Fast EU Authorized Representative transfer with minimal disruption✔ Single, trusted EU Importer and Authorized Representative under one contract✔ Full support for MDR, IVDR, medical devices, IVDs, and regulated products✔ Expertise in CE marking, EU compliance, technical documentation, and vigilance✔ Clear communication, transparent pricing, and[…]

Australian TGA Medical Device Sponsor

January 12, 2026 adminTGA Sponsor

As per the Australian TGA Medical Device Regulations, before an individual or company can supply a medical device for sale in Australia, they are required to make an application to include the item in the Australian Register of Therapeutic Goods (ARTG). This registration is crucial for ensuring that the medical devices comply with Australian health standards and are safe for use by the public. The sponsor is defined as the person or company responsible for the importation of therapeutic goods into Australia, playing a vital role in the compliance process. The importance of having a reliable sponsor cannot be overstated. A well-informed sponsor familiar with Australian regulations can expedite the[…]

This New Year, invest in your professional growth and strengthen your regulatory knowledge to stay ahead in the dynamic world of medical devices.

January 12, 2026 adminTGA Sponsor

CMS SciDoc invites Expressions of Interest for our Medical Device Training Programmes – 2026, designed to empower professionals with practical expertise and up-to-date insights into global regulatory requirements.Our programs are crafted and delivered by experienced medical device consultants, blending regulatory theory with real-world, hands-on application to help you achieve compliance confidence. Who should attend?💠 Regulatory Affairs & Quality professionals💠 Medical device manufacturers & sponsors💠 Start-ups entering the medical device market💠 R&D, Clinical, QA/RA, and Compliance teams Proposed training topics:💠 ISO 13485 – Quality Management Systems for Medical Devices💠 ISO 14971 – Risk Management for Medical Devices💠 Process Validation for Medical Devices💠 Medical Device Software💠 Auditor Training💠 Designing a Regulatory Compliant Technical File💠 Clinical Evaluation Report: Tips & Tricks💠 MDSAP[…]

TGA Regulatory changes to software-based medical devices

July 9, 2024 gloizouTGA Sponsor

Just a reminder to all Medical device software manufacturers and in light of the TGA’s recently published regulatory changes to software-based medical devices, up-classification to most medical device software is almost a definite. Terminology such as screening, risk factor, etc., cannot be considered as class I SaMD. Contact us for a preliminary assessment.

MEDSAFE published the updated document

July 8, 2024 gloizouTGA Sponsor

MEDSAFE published the updated document “Guidelines on the Regulation of Therapeutic Products in New Zealand,” Edition 2, in May 2024, which provides an overview of therapeutic product regulation in New Zealand.